Sodium cyclamate and cyclohexylamine
These substances were identified for action under the Chemicals Management Plan (CMP).
|CAS RN||Common name||DSL name||Draft screening assessment||Proposed conclusion on section 64 criteria||Follow-up activities|
|139-05-9||Sodium cyclamate||Sulfamic acid, cyclohexyl-, monosodium salt||HTML||Does not meet||Under consideration|
|December 2020||Anticipated publication of the final screening assessment.|
|December 14, 2019||Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 50.|
Cyclohexylamine (CAS RN 108-91-8) was identified as being part of the Aliphatic Amines Group at the outset of the third phase of the CMP. This substance was subsequently moved to this assessment of sodium cyclamate, since cyclohexylamine is a metabolite of sodium cyclamate in mammals and cyclohexylamine data were used to assess the risk to human health of both substances.
Report a problem or mistake on this page
- Date modified: